Stock Analiz

Cytek Biosciences, Inc. (CTKB) stock forecast and price target

Price $5.84 · data as of November 13, 2026

12-month price target

Average target$6.50
Upside / downside+11.3%
Analysts3
ConsensusBuy
Low $5.00Average $6.50High $7.50

Gold marker: average target · white marker: today’s price ($5.84)

Analyst ratings

Strong buy 1Buy 1Hold 1Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-0.29—$209M
Next fiscal year
ends December 31, 2027
$-0.18—$223M
Next quarter
ends December 31, 2026
$0.01—$63M
Quarter after
ends March 31, 2027
$-0.08—$48M

Consensus of the analysts covering Cytek Biosciences, updated daily. In the last 30 days 0 estimates were raised and 2 lowered.

Our model vs. Wall Street

Analysts see 11.3% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Cytek Biosciences’s intrinsic value about 84% below today’s market value, and it scores 1.0 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the Cytek Biosciences stock price target?

The average 12-month target from 3 analysts is $6.50, 11.3% above the current price of $5.84 Targets range from $5.00 to $7.50.

Is Cytek Biosciences a buy according to analysts?

The consensus rating is “Buy” (1 strong buy, 1 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.

How much is Cytek Biosciences expected to earn?

Analysts expect EPS of $-0.29 for the fiscal year ending December 31, 2026 and $-0.18 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.